García GAE, Lezama VP

Language: Spanish
References: 11
Page: 100-108
PDF size: 177.49 Kb.

ABSTRACT

Introduction. The hepatoblastoma (HB) is a malignant tumor of the liver low incidence whose cases have not been described in the state of Puebla according to international classifications. Objective: To describe the clinical characteristics of patients diagnosed with HB who have been treated at a tertiary pediatric hospital. Material and methods. Descriptive, retrospective and cross-sectional design. Results. 21 cases were analyzed, predominantly male, age 23.4 ± X ̅ = 20.4 months; Survival X ̅ = 12.2 ± 20 months, R = 1-85 months. 28% had metastases. They were classified into PRETEX I = 4.7% = 28.5% II, III and IV = 23.9% = 42.9%. Discussion and conclusions: the lack of therapeutic addiction SIOPEL is clear. Many cases of HB were diagnosed in advanced stages according to the PRETEXT classification, resulting in high mortality. It is necessary have screening programs to trate of HB in initial stages, increasing the average survival. The findings, represents a guideline for future research, since they have no precedent in the state of Puebla, but the results should be taken with reservation to reason that the sample size is not statistically sufficient

REFERENCES

1. 1.- Buckley JD, Sather H, Ruccione K, Rogers PC, Haas JE, Henderson BE, et al. A case-control study of risk factors for hepatoblastoma. A report from the Childrens Cancer Study Group. Cancer 1989;64:1169-76.

2. 2.- Surveillance Epidemiology and End Results Program. Availablefrom:http://www.seer.cancer.gov [Cancer Statistics Review 1975-2009].

3. 3.- Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012;59:776-9

4. 4.- Palomo-Colli M.A. , Juárez-Villegas L.E., Lezama-Del Valle P.,Cruz-Carrasco A.E., Peña- Del Castillo H. et. al. Resultados del tratamiento de niños con hepatoblastoma en el Hospital Infantil de México Federico Gómez. Gaceta Mexicana de Oncología (2013).No1(12):10-18

5. 5.- Aronson DC, Czauderna P, Maibach R, Perilongo G, Morland B. The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials . J Indian Assoc Pediatr Surg 2014;19:201-7

6. 6.- Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841

7. 7.- Sotelo-Avila C, Gonzalez-Crussi F, Fowler JW. Complete and incomplete forms of Beckwith Wiedemann syndrome: their oncogenic potencial. J Pediatr 1980;96:47-50.

8. 8.- G.-L. Qiao, L. Li, , , W. Cheng, J. Ge, Z. Zhang et al Predictors of survival after resection of children with hepatoblastoma: A single Asian center experience show more Show less. European Journal of Surgical Oncology (2014) No 11(40):1533–1539

9. 9.- Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: Results from the international society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol 2005;23:1245-52.

10. 10.- Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F, et al.; International Childrhood Liver Tumor Strategy Group 2005 PRETEXT: A revised staging system for primary malignant liver tumors of childhood developed by the SIOPEL group. Pediatr Radiol 2007;37:123-32

11. 11.- Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art: Pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr 2014;26:29-36 Rev.